13F Holdings
中文EN

BDRX Biodexa Pharmaceuticals Plc IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1643918 · Reporting currency GBP · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-45.5%
TTM net income YoY7.5%
TTM EPS YoY98.7%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,103.4%
Net margin-1,858.0%
FCF margin-1,798.4%
EBITDA margin—

Returns

ROE-180.6%
ROA-88.1%
ROIC (approx.)-10,464.6%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets55.6%
Debt / equity0.10x
Current ratio1.26x
Interest coverage-195.46x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue6.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: GBP FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue——381,000699,000578,000
R&D expense3.96M5.44M4.07M5.11M4.65M
Operating income-8.64M-9.20M-8.01M-8.93M-7.00M
Interest expense229,000165,00041,00053,00044,000
Pretax income-6.49M-5.98M-7.49M-8.49M-6.11M
Income tax-105,000-250,000-406,000-832,000-646,000
Net income-6.38M-5.73M-7.08M-7.66M-5.46M
EPS (basic)-0.00-0.00-0.02-1.55—
EPS (diluted)-0.00-0.00-0.02-1.55—
Balance sheet
Cash & equivalents8.53M1.67M5.97M2.84M10.06M
Receivables3.79M6.57M637,0001.01M1.03M
Current assets12.44M8.81M7.03M4.69M11.76M
PP&E, netmay include right-of-use assets (IFRS)91,000324,000571,000831,0001.15M
Total assets18.18M14.78M10.54M5.53M12.91M
Current liabilities6.13M5.03M5.57M1.90M1.84M
Short-term debt61,000609,000169,000161,000146,000
Long-term debt—118,000295,000463,000620,000
Total debt—727,000464,000624,000766,000
Total liabilities6.77M6.46M5.86M2.36M2.46M
Shareholders' equity11.40M8.32M4.68M3.16M10.45M
Net debt—-942,000-5.51M-2.21M-9.29M
Shares outstanding————6.74B
Cash flow statement
Operating cash flow-5.59M-12.26M-6.83M-7.05M-6.01M
Capital expenditure2,0009,00026,00062,000320,000
Free cash flow-5.59M-12.27M-6.85M-7.11M-6.33M
Investing cash flow-583,000-598,000-265,000-220,000-278,000
Financing cash flow13.04M8.56M10.23M47,0008.80M
Stock-based compensation170,000283,00028,000123,00089,000

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.